Canaccord analyst William Plovanic raised the firm’s price target on Pulmonx to $16 from $15 and keeps a Buy rating on the shares. The firm said management reiterated its FY24 guidance and noted that it was remaining conservative given the unpredictable historical seasonality the comany has experienced in the past, especially in the US.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUNG:
- Pulmonx Reports Second Quarter 2024 Financial Results
- Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
- Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
- Lake Street highlights five ‘bargain bin’ small cap healthcare ideas for 2H
- Pulmonx initiated with a Buy at Lake Street